Neurological disorders news - the latest biotech news

Home Neurological disorders Page 11

Latest Posts

News and Trends 30 Sep 2016

Interview: GeNeuro’s CFO explains its Unique Multiple Sclerosis Treatment

GeNeuro is developing a unique treatment for multiple sclerosis. We interviewed Miguel Payro, the company’s CFO, who explained its advantageous position against big pharma. GeNeuro raised €33M in its Euronext IPO in April and is currently competing against giants like Novartis and Biogen. Despite 2016’s dubious honor as “the worst year for IPO in 20 years”, this Switzerland-based company has managed to go […]

September 30, 2016 - 1 minutemin - By Clara Rodríguez Fernández

synapses neurons alzheimers Bruce Rolff fi

News and Trends 27 Sep 2016

Another “Almost” against Alzheimers: Lundbeck’s Phase III Flop

Alzheimer’s Disease is the most common form of dementia, affecting 15M people across the world. With the most recent failure of idalopirdine, a cure will remain elusive for now. As Derek Lowe observes, “Alzheimers therapies have, for the most part, been a cliff over which people push bales of money.” Unfortunately, the late-stage failure of […]

September 27, 2016 - 2 minutesmins - By Evelyn Warner

brain by vitstudio featured image

News and Trends 26 Sep 2016

UPDATE: AC Immune rakes in €52.5M IPO for assault on Alzheimers

It’s not the $700M headlines imply, but AC Immune is winding up to make a splashy IPO of €52.5M to establish itself in the Alzheimer’s Disease space. You might have read about AC Immune‘s ‘$700M IPO’ and thought, “gee, that can’t be right – that sum is roughly half of the total from all European companies […]

September 26, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 11 Feb 2016

Sanofi-Genzyme: Still successful 5 years after the acquisition?

Back in 2011, France’s biggest Pharmaceutical company Sanofi decided to purchase Genzyme Corp. for more than $20 billion, thus becoming the latest global drug giant to acquire a big biotech to foster its R&D pipeline. 5 years later, what’s the situation for Genzyme and Sanofi? So often when a large Pharma acquires a smaller Biotech, […]

February 11, 2016 - 3 minutesmins - By Dani Bancroft

ADVERTISEMENT